Media
Media
August 28, 2026
CURE
Soquelitinib Monotherapy Shrank Tumors in Pretreated T-Cell Lymphoma
June 16, 2026
PharmaVoice
Corvus CEO thinks his next blockbuster is an ITK inhibitor
May 26, 2026
Dermatology Times
Soquelitinib Demonstrates Efficacy in Atopic Dermatitis After Systemic Failure
May 21, 2026
Dermatology Times
ITK Inhibition With Soquelitinib Yields Sustained Skin Clearance Up to 90 Days Off Therapy
April 2, 2026
HealthCentral
An Eczema Pill for Everyone? What Experts Say So Far
January 28, 2026
BioTech TV
Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
December 8, 2025
BioTech TV
ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know
Our Science
We are developing immunology focused medicines that target the most critical cellular elements of the immune system
Who We Are
We are committed to developing better medicines to improve the lives of people with immune diseases and cancer
